Pyrethroid PBPK Modeling Meeting with the Council for the Advancement of Pyrethroid Human Risk Assessment (CAPHRA). On May 27, 2020, CAPHRA members met with OPP staff from PRD and HED via web and teleconference to discuss additional PBPK modeling for the calculation of data derived extrapolation factors (DDEFs) and new points of departure (PoDs) for the pyrethroids. CAPHRA sought clarification on EPA comments related to issues with dose metrics and precision in model prediction. While no longer facing the urgency of two years ago to reduce the uncertainty/safety factors for pyrethroids (for registration review deliverables), CAPHRA is currently searching for ways to improve future PBPK modeling. CAPHRA hopes this work will support continued/new uses for products containing pyrethroid active ingredients in the future and does not intend to complete this goal in time for consideration in registration review. Several pyrethroid IDs are scheduled to be completed in September 2020. (Carolyn Smith, Chemical Review Manager, PRD, 703-347-8325)

